{"entity":{"id":"nct06508216","kind":"trial","name":"A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat","aka":["COMPASS-TNBC"],"tldr":"A phase 1/2 trial of datopotamab deruxtecan and durvalumab in triple-negative breast cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","summary":"A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer is a phase 1/2, randomised interventional study registered as NCT06508216 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 50 participants, started 2024-07-05 and due to reach its primary completion in 2025-12-17. Interventions recorded: Dato-DXd; Durvalumab. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: \"Patients who have early relapsed triple negative breast cancer i\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06508216","url":"https://clinicaltrials.gov/study/NCT06508216"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","tnbc-metastatic"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["datopotamab-deruxtecan","durvalumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06508216","phase":"1/2","setting":"A Phase Ib/II, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06508216/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}